Nivolumab (ONO-4538)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Nivolumab (ONO-4538), covering 2024-04-16 to 2024-09-05. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) [Phase 3]